ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2208

Referral Patterns and Diagnosis of Patients with Axial Spondyloarthritis: Results of an International Survey

Désirée van der Heijde1, Joachim Sieper2, Dirk Elewaut3, Aileen L. Pangan4 and Dianne Nguyen5, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, 3Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, 4Abbott Laboratories, Abbott Park, IL, 5Abbott Laboratories, Singapore, Singapore

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: This analysis compares referral patterns and diagnostic tools for axial spondyloarthritis (axSpA) used by rheumatologists working in academic centers and in community clinical practice settings.

Methods: The MAXIMA (Management of Axial SpA International and Multicentric Approaches) survey asked respondents questions pertaining to referral, diagnosis, and management of patients with axSpA. The survey was completed anonymously online by participants from 42 countries in Europe, Latin America, and North America. The MAXIMA survey was funded by Abbott Laboratories and conducted by a third-party vendor with guidance and approval of the questionnaire by a steering committee of SpA experts. None of the participants were compensated for completing the survey. 

Results: 500 surveys were completed by 141 rheumatologists in academic practice settings (28%) and 359 rheumatologists in community practice settings (72%). Only 58% of academic rheumatologists compared to 72% of clinical rheumatologists agreed that the concept of axial SpA is clear to the rheumatology community. However, responses to various questions about referral and diagnostic work-up for patients with axSpA were generally similar in both practice settings (table). The majority of respondents (87%) reported that primary care providers referred patients with chronic back pain for 3 months and onset <45 yrs old; 47% of respondents received referrals from other specialists such as dermatologists, gastroenterologists, and ophthalmologists. Other than chronic and inflammatory back pain, referrals from non-rheumatology specialists were triggered by the occurrence of uveitis (82%), inflammatory bowel disease (48%) and skin lesions (46%). At the time of referral to the rheumatologist, 48% of patients have symptoms for ≥3 yrs. The ASAS criteria (85%) were cited as the most common classification criteria that guide respondents in the diagnosis of axSpA in clinical practice, compared to the modified New York criteria for AS (23%), ESSG (8%), and Amor (6%). In terms of diagnostic work-up, approximately half systematically request HLA-B27 typing. MRI of the sacroiliac joints is the most commonly used imaging test, closely followed by pelvic x-rays.

Conclusion: Results of the MAXIMA survey show general agreement in referral patterns and use of diagnostic tools by rheumatologists in academic and clinical practice settings when evaluating patients for axSpA. Half of the patients are still being seen by rheumatologists several years after onset of symptoms, which indicates the need for appropriate early referral.

 

Table. Response rates in MAXIMA survey regarding SpA referral patterns and diagnosis

Question

Rheumatology Practice Setting

Overall

N=500

Academic Center

N=141

Community Clinical Practice

N=359

Patients with back pain ≥3 mo, <45 yrs old

Source of referralsa

Primary care provider

82

89

87

Physiotherapist

18

30

27

Private office rheumatologist

22

18

19

Other specialistb

50

46

47

Duration of symptoms

<1 yr

9

10

10

1–2 yrs

36

45

42

3–4 yrs

41

30

33

>5 yrs

14

15

15

Triggers of past referrals from other specialists

Uveitis

81

82

82

Chronic back pain

69

64

65

IBP

38

44

42

Skin lesions

47

45

46

Nail lesions

23

30

28

Inflammatory bowel disease

45

49

48

Diagnosis in daily practice

Classification guides used for diagnosis of axSpA in practice

ASAS

92

83

85

Modified New York criteria for AS

21

24

23

ESSG 

4

10

8

HLA-B27 typing performed routinely

49

50

49

Imaging tests used

MRI sacroiliac joint

92

93

93

Pelvic x-ray

88

85

86

Spinal x-ray

71

78

76

MRI spine

56

58

57

aRespondents may have indicated >1 source of referrals. bOther specialist = dermatologist, gastroenterologist, ophthalmologist. AS, ankylosing spondylitis; ASAS, Assessments in Spondyloarthritis International Society; axSpA, axial spondyloarthritis; ; BASDAI, Bath AS Disease Activity Index; ESSG, European Spondylarthropathy Study Group; IBP, inflammatory back pain; mo, months; MRI, magnetic resonance imaging; SpA, spondyloarthritis; yr, year.


Disclosure:

D. van der Heijde,

Abbott Laboratories; Amgen; AstraZeneca; BMS; Centocor: Chugai; Eli-Lilly; GSK; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Schering-Plough; UCB; Wyeth,

5,

Abbott Laboratories; Amgen; AstraZeneca; BMS; Centocor: Chugai; Eli-Lilly; GSK; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Schering-Plough; UCB; Wyeth,

2,

Imaging Rheumatology,

4;

J. Sieper,

Abbott, Merck, Pfizer, and UCB,

2,

Abbott, Merck, Pfizer, and UCB,

5,

Abbott, Merck, Pfizer, and UCB,

8;

D. Elewaut,

Abbott Laboratories,

2,

Abbott Laboratories,

8;

A. L. Pangan,

Abbott Laboratories,

3,

Abbott Laboratories,

1;

D. Nguyen,

Abbott Laboratories,

3,

Abbott Laboratories,

1.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/referral-patterns-and-diagnosis-of-patients-with-axial-spondyloarthritis-results-of-an-international-survey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology